

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
12 September 2003 (12.09.2003)

PCT

(10) International Publication Number
WO 03/074485 A2(51) International Patent Classification⁷: C07D 209/42,
A61K 31/404, A61P 43/00David [GB/GB]; AstraZeneca R & D Alderley, Alderley
Park, Macclesfield, Cheshire SK10 4TG (GB).

(21) International Application Number: PCT/GB03/00936

(74) Agent: ASTRAZENECA; Global Intellectual Property,
Mereside, Alderley Park, Macclesfield, Cheshire SK10
4TG (GB).

(22) International Filing Date: 4 March 2003 (04.03.2003)

(25) Filing Language: English

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VC, VN, YU, ZA, ZM, ZW.

(26) Publication Language: English

(30) Priority Data:
0205166.2 6 March 2002 (06.03.2002) GB(71) Applicant (*for AE, AG, AL, AM, AT, AU, AZ, BA, BB, BE,
BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CY, CZ, DE,
DK, DM, DZ, EC, EE, ES, FI, FR, GB, GD, GE, GH, GM,
GR, HR, HU, ID, IE, IL, IN, IS, IT, JP, KE, KG, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MC, MD, MK, MN,
MW, MX, MZ, NL, NO, NZ, OM, PH, PL, PT, RO, RU, SC,
SD, SE, SG, SK, SL, SZ, TJ, TM, TN, TR, TT, TZ, UA, UG,
UZ, VC, VN, YU, ZA, ZM, ZW only*): ASTRAZENECA
AB [SE/SE]; Sodertalje, S-151 85 (SE).(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI,
SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).(71) Applicant (*for MG only*): ASTRAZENECA UK LIM-
ITED [GB/GB]; 15 Stanhope Gate, London, Greater Lon-
don W1K 1LN (GB).


Published:

— without international search report and to be republished
upon receipt of that report

(72) Inventor; and

(75) Inventor/Applicant (*for US only*): MORLEY, Andrew,For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: CHEMICAL COMPOUNDS



(1)

(57) Abstract: Heterocyclic amides of formula (1) (A chemical formula should be inserted here - please see paper copy enclosed herewith) (1) wherein: R¹ is independently selected from, for example, C₁₋₆alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkylC₁₋₃alkyl, C₁₋₆alkoxy, C₃₋₇cycloalkoxy, C₃₋₇cycloalkylC₁₋₃alkoxy, heterocyclyl, heterocyclylC₁₋₃alkyl, heterocyclylC₁₋₃alkoxy; R² is phenyl or heteroaryl; R³ is independently selected from hydrogen, halo, nitro, cyano, hydroxy, carboxy, carbamoyl, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, fluoromethyl, difluoromethyl, trifluoromethyl and trifluoromethoxy; or a pharmaceutically acceptable salt or pro-drug thereof; possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity. Processes for the manufacture of said heterocyclic amide derivatives and pharmaceutical compositions containing them are described.